Identification of degradation products in Aripiprazole tablets by LC-QToF mass spectrometry

Gosula Venkat Rami Reddy, Avvaru Praveen Kumar, Bobba Venkateswara Reddy, Poonam Kumar, Ham Dutt Gauttam

Abstract


This paper describes the separation, identification and proposed structures of the degradation products formed during degradation analysis of aripiprazole in its final dosage form by high performance liquid chromatography (HPLC) coupled with quadrupole time-of-flight mass spectrometry (QToF-MS). The drug product was subjected to stress conditions including acid, base, thermal, oxidation, humidity and photolytic degradations. Aripiprazole was found to be stable in all conditions except in thermal and peroxide degradations. The degradation impurities were first separated by HPLC and then identified using QToF mass spectrometry. QToF mass spectrometer provided high order of mass accuracy for unknown impurities and their fragment ions to explore the elemental composition. Based on the fragmentation pattern, the possible structures of the unknown impurities were proposed. To the best of our knowledge, there were no methods available to identify the impurities during degradation of aripiprazole tablets by liquid chromatography-mass spectrometry.

1_1_20_27_800


Keyword(s)


Aripiprazole; Identification of degradation impurities; LC-QToF-MS; HPLC

European Journal of Chemistry, 1 (1), (2010), 20-27

Full Text:

PDF    /    /

DOI: http://dx.doi.org/10.5155/eurjchem.1.1.20-27.11


References

[1]. Tamminga, C. A. J. Neural Transm. 2002, 109, 411-420.
doi:10.1007/s007020200033
PMid:11956961

[2]. Burris, K. D.; Molski, T. F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F. D.; Molinoff, P. B. J. Pharmacol. Exp. Ther. 2002, 302, 381-389.
doi:10.1124/jpet.102.033175
PMid:12065741

[3]. Jordan, S.; Koprivica, V.; Chen, R.; Tottori, K.; Kikuchi, T.; Altar, C.A. Eur. J. Pharmacol. 2002, 441, 137-140.
doi:10.1016/S0014-2999(02)01532-7

[4]. Hirose, T.; Uwahodo, Y.; Yamada, S.; Miwa, T.; Kikuchi, T.; Kitagawa, H.; Burris, K. D.; Altar, C. A.; Nabeshima, T. J. Psychopharmacol. 2004, 18, 375-383.
doi:10.1177/026988110401800308
PMid:15358981

[5]. Kane, J. M.; Carson, W. H.; Saha, A. R.; McQuade, R. D.; Ingenito, G. G.; Zimbroff, D. L.; Ali, M. W. J. Clin. Psychiatry 2002, 63, 763-771.

[6]. Potkin, S. G.; Saha, A. R.; Kujawa, M. J.; Carson, W. H.; Ali, M.; Stock, E.; Stringfellow, J.; Ingenito, G.; Marder, S. R. Arch. Gen. Psychiatry 2003, 60, 681-690.
doi:10.1001/archpsyc.60.7.681
PMid:12860772

[7]. Kasper, S.; Lerman, M. N.; McQuade, R. D.; Saha, A.; Carson, W. H.; Ali, M.; Archibald, D.; Ingenito, G.; Marcus, R.; Pigott, T. Int. J. Neuropsychopharmacol. 2003, 6, 325-337.
doi:10.1017/S1461145703003651
PMid:14609439

[8]. Ribeiro, Y. A.; de Oliveira, J. D. S.; Leles, M. I. G.; Juiz, S. A.; Ionashiro, M. J. Therm. Anal. 1996, 46, 1645-1655.
doi:10.1007/BF01980770

[9]. Zhou, W.; Gilpin, R. K. J. Pharm. Sci. 2004, 93, 1545-1556.
doi:10.1002/jps.20082
PMid:15124212

[10]. Berridge, J. C. J. Pharm. Biomed. Anal. 1995, 14, 7-12.
doi:10.1016/0731-7085(95)01573-6

[11]. Branch, S.K. J. Pharm. Biomed. Anal. 2005, 38, 798-805.
doi:10.1016/j.jpba.2005.02.037
PMid:16076542

[12]. Roy, J. AAPS PharmSciTech 2002, 3, 1-8.
doi:10.1208/pt030206
PMid:12916943

[13]. Zuo, X. C.; Wang, F.; Xu, P.; Zhu, R. H.; Li, H. D. Chromatographia, 2006, 64, 387-391.
doi:10.1365/s10337-006-0037-1

[14]. Masanori, K.; Yasuo, M.; Yukihiro, H.; Takahiko, O. J. Chromatogr. B 2005, 822, 294-299.
doi:10.1016/j.jchromb.2005.06.023
PMid:16005688

[15]. Hui-Ching, H.; Chin-Hung, L.; Tsuo-Hung, L.; Tsung-Ming, H.; Hsien-Jane, C.; Yu-Chun, W.; Ying Lung, T. J. Chromatogr. B, 2007, 856, 57-61.
doi:10.1016/j.jchromb.2007.05.026
PMid:17602901

[16]. Shah, V. P.; Kamal, K. M.; Shrikant, D.; Iain, J. M.; Jerome, P. S.; Avraham, Y.; Thomas, L.; Viswanathan, C. T.; Edgar, C.; McDowall, R. D.; Kenneth, A. P.; Sidney, S. J. Pharm. Sci. 1992, 81, 309-312.
doi:10.1002/jps.2600810324

[17]. Zha, J. P., Xu, H. J., Wang, Y. Z., Yang, S. G., Jia, C. X., Hou, Z. F. Chin. Pharm. J. 2005, 40, 137-139.

[18]. Srinivas, K. S. V.; Buchireddy, R.; Madhusudhan, G.; Mukkanti, K.; Srinivasulu, P. Chromatographia 2008, 68, 635-640.
doi:10.1365/s10337-008-0739-7

[19]. ICH Topic Q1A (R2) 2003 Stability Testing of new Drug Substances and Products, CPMP/ICH/2736/99.

[20]. Lacorte, S.; Fernandez-Alba, A. R. Mass Spectrom. Rev. 2006, 25, 866-880.
doi:10.1002/mas.20094
PMid:16752429

[21]. Schmid, R. P.; Weickhardt, C. Int. J. Mass Spectrom. 2001, 206, 181-190.
doi:10.1016/S1387-3806(00)00311-0

[22]. Ferrer, I.; Garcı’a-Reyes, J. F.; Fernandez-Alba, A. Trends in Anal. Chem. 2005, 24, 2005.

[23]. Petrovic, M.; Gros, M.; Barcelo, D. J. Chromatogr. A 2006, 1124, 68-81.
doi:10.1016/j.chroma.2006.05.024
PMid:16759662

[24]. (WO/2003/064393) Thio-carbostyril derivative, its N-oxides and the N-oxides of aripiprazole.


Refbacks

  • There are currently no refbacks.